


WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number: WO 98/25533
A61B 17/39	A1	(43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/US (22) International Filing Date: 9 December 1997 (DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 032,804 792,094 9 December 1996 (09.12.96 31 January 1997 (31.01.97) (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US// SciMed Place, Maple Grove, MN 55311–1566 (U) (72) Inventor: HEKTNER, Thomas, R.; 825 Navajo Road	US]; O IS).	
MN 55340 (US). (74) Agents: SEAGER, Glenn, M. et al.; Crompton, Seage LLC, Suite 895, 331 Second Avenue South, Min MN 55401-2246 (US).	er & Tu	e

(54) Title: RADIO FREQUENCY TRANSMYOCARDIAL REVASCULARIZATION CORER



(57) Abstract

This invention is an RF activated catheter apparatus (100) for performing transmyocardial revascularization. The catheter apparatus includes an elongate catheter shaft (118) having proximal and distal ends, the distal end including an RF emitter (148) which is coupled to an RF generator (26) for cutting channels into the myocardium of a patient's heart.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

ı								
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia	
AM		FI	Finland	LT	Lithuania	SK	Slovakia	
AT	Austria	FR	France	LU	Luxembourg	SN		
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Senegal Swaziland	
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad	
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo	
BB	Barbados	GH	Ghana	MG	Madagascar	T.J	•	
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Tajikistan	
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkmenistan	
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Turkey	
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Trinidad and Tobago	
BR	Brazil	IL	Israel	MR	Mauritania	UG	Ukraine	
BY	Belarus	IS	Iceland	MW	Malawi	US	Uganda	
CA	Canada	IT	Italy	MX	Mexico		United States of America	
CF	Central African Republic	JP	Japan	NE.	Niger	UZ	Uzbekistan	
CG	Congo	KE	Kenya	NL	Netherlands	VN	Viet Nam	
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia	
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	zw	Zimbabwe	
CM	Cameroon		Republic of Korea	PL	Poland			
CN	China	KR	Republic of Korea	PT				
CU	Cuba	KZ	Kazakstan	RO	Portugal Romania			
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation			
DE	Germany	u	Liechtenstein	SD	Sudan			
DK	Denmark	LK	Sri Lanka	SE				
EE	Estonia	LR	Liberia	SG SG	Sweden			
		Lik	Liberia:	36	Singapore			

RADIO FREQUENCY TRANSMYOCARDIAL REVASCULARIZATION CORER Related Cases

This application claims the benefit of U.S.

Provisional Application No. 60/032,804, filed December 9,

1996. The present application is related to U.S. Patent

Application Serial No.________, filed _________,

entitled "Radio Frequency Transmyocardial Revascularization", and is incorporated herein by reference.

10

Field of the Invention

The present invention pertains to a device and method for performing transmyocardial revascularization (TMR) using radio frequency (RF) energy.

15

Background of the Invention

A number of techniques are available for treating cardiovascular disease such as cardiovascular bypass surgery, coronary angioplasty, laser angioplasty and atherectomy. These techniques are generally applied to bypass or open lesions in coronary vessels to restore or increase blood flow to the heart muscle. In some patient's the number of lesions is so great, or the location so remote in the patient's vasculature, that restoring adequate blood flow to the heart muscle is difficult.

TMR has been developed as an alternative to these techniques which are directed at bypassing or removing lesions. TMR is performed by boring channels directly into the myocardium of the heart. In one such procedure, a laser catheter is advanced into the left ventricle. Laser radiation is then focused on the myocardium to create a channel. It has been found that creating several channels may be useful.

TMR has been performed by forming channels with laser energy as described above. TMR has also been performed by cutting a channel with a sharpened probe or blade. The channels cut by laser have a width proportional to the width of the focused laser radiation used to make the channels. When a laser is used, tissue is vaporized to form the channel. When the procedure is performed with a blade, tissue is not removed, but merely pierced or cut.

Lasers used to performed TMR can be costly and the depth of the channels formed can be difficult to control.

20 Cutting the myocardium with a blade does not remove material from the incision. Removing, or in the case of the TMR laser techniques, vaporization of tissue is believed to enhance the success of the TMR procedure.

Summary of the Invention

The present invention pertains to an apparatus and method for performing TMR using RF energy. The apparatus and method of the present invention provides a means for performing TMR by creating channels in the myocardium of the patient's heart which can vary in length and width. The depth of the channels is generally believed to be directly proportional to the distance which the catheter of the present invention is advanced into the patient's myocardium.

Two theories underlie this procedure. The leading theory holds that creation of the channels causes angiogenesis as a healing response. When angiogenesis occurs, additional blood vessels grow in the myocardium near the channels. The second theory of TMR is that the creation of channels provides direct access of pooled blood in the heart to the heart muscle.

In one embodiment of the present invention, an RF activated catheter is provided for boring channels into the myocardium of a patient's heart. The RF activated catheter includes an elongate shaft having a proximal end and a distal end. A lumen extends through the shaft between the proximal and distal ends. A cutting tip is disposed at the distal end of the shaft. The cutting tip has proximal and distal ends and a lumen extending therebetween in fluid communication with the shaft lumen.

A wire connects the cutting tip to an RF generator. The distal end of the tip is sharpened.

The catheter is used in a catheter assembly including an RF generator coupled to the cutting tip. A vacuum source is connected to the catheter proximate its proximal end and is in fluid communication with the catheter shaft lumen.

The catheter assembly preferably includes a second catheter having a proximal end and a distal end and a lumen extending therethrough between the ends. The first catheter can be advanced through the lumen of the second catheter. The second catheter preferably includes a balloon disposed around and at its distal end. An inflation lumen is provided through the second catheter in fluid communication with the balloon.

To perform TMR using this catheter assembly, the cutting tip is advanced to the patient's heart. This is preferably done percutaneously via the femoral artery. The RF generator is activated to deliver RF energy to the cutting tip. The cutting tip is advanced into the myocardium of the patient's heart to form channels therein. A second catheter can be disposed over the distal cutting tip to isolate the cutting tip from pooled blood within the patient's ventricle. Tissue within the cutting tip can be aspirated through the RF activated catheter.

Brief Description of the Drawings

Figure 1 is a cut-away view of a human heart including an RF transmyocardial revascularization catheter apparatus in accordance with the present invention;

Figure 2 is a diagram of the RF transmyocardial revascularization assembly including RF generator ground plane and catheter; and

Figure 3 is a cross sectional view of the distal end 10 of the catheter apparatus of Figure 2.

Detailed Description of the Invention

Referring now to the drawings wherein like reference numerals represent like elements throughout the several views, Figure 1 is a view of a portion of an radio frequency transmyocardial revascularization (RF TMR) catheter assembly 100 disposed within an aorta 12 and a left ventricle 14 of a heart 16. The elements of catheter assembly shown in Figure 1 include an RF activated catheter 118, partially extending from a tubular catheter 120. Catheter 118 can be deflectable or steerable with wires (not shown). Catheter 120 can be a guide catheter, deflectable tip catheter or the like, for advancing RF activated catheter 118 therethrough or to shield portions of a patient's anatomy from RF energy emitted from catheter 118. Three channels 22 cut by

catheter 118 are shown in myocardium 24 of heart 16. As a consequence of creating these channels by performing the TMR procedure, it is believed that revascularization of the myocardium near the channels occurs by angiogenesis, the channels themselves provide access by pooled blood from ventricle 14 to myocardial tissue or both.

Figure 2 is an embodiment 100 of the RF TMR catheter assembly in accordance with the present invention.

10 Embodiment 100 includes an RF activated catheter 118 electrically connected at its proximal end near handle 136 to RF generator 26 by cable 34. Disposed at the distal end of catheter 118 is a cutting tip 148. A vacuum generator 156 is fluidly connected by tube 158 to 15 catheter 118 at a tee 160, which is in turn is in fluid communication with distal tip 148 by way of a lumen (Figure 3) 162 extending through catheter 118. Vacuum generator 156 is connected to a power source by way of cable 164 to remove tissue to avoid embolizing or to take 20 a specimen.

Catheter 118 as shown in Figure 2 is disposed through a tubular catheter 120 having a balloon 166 disposed at its distal end. Disposed at the proximal end of catheter 120 is an adaptor 140 having a side arm 142 in fluid communication with a central lumen 168 (Figure 3) extending through catheter 120. A second side branch

PCT/US97/22591 WO 98/25533

170 of adaptor 140 is in fluid communication with an inflation lumen 172 (Figure 3) extending through catheter 120 to balloon 166.

Figure 3 is a cross sectional view of the distal 5 ends of catheters 118 and 120. In this view, the distal end of catheter 120 abuts a heart wall 174 of heart 16. Distal cutting tip 148 of RF activated catheter 118 is Balloon 166 is shown shown extended into wall 174. inflated to shield pooled blood from RF energy. Catheter 10 120 and balloon 166 can be formed from typical guide catheter and angioplasty balloon materials, respectively, as well known to those skilled in the art.

Catheter 118 preferably includes a shaft portion 176 defining a portion of lumen 162 extending proximally from 15 cutting tip 148, tip 148 defines the distal-most portion Shaft 176 is readily formed from a of lumen 162. biocompatible polymer well known to those skilled in the art of catheter construction having sufficient rigidity to allow cutting tip 148 to be pushed into heart wall 174.

20

Cutting tip 148 preferably has a sharpened distal edge 178 surrounding the distal opening of lumen 162. Tip 148 can include a sharp point 180 similar to that of hypodermic needle. The cutting tip 148 is preferably 25 formed from stainless steel or other biocompatible metal. The proximal end of tip 148 is bonded or adhered to the

distal end of shaft 176 in a manner known to those skilled in the art. The length of tip 148 varies according to channel requirement. In an exemplary embodiment, the outside diameter of cutting tip 148 is one millimeter and the inside diameter is 0.9 millimeters, but may vary depending on channel width desired. An RF transmission wire 182 connects cutting tip 148 to the proximal end of catheter 118 for interconnection with the RF generator 26.

In use, the cutting tip 148 of catheter 118 and the 10 distal end of catheter 120 are advanced to the patient's heart 16, the hybernatory tissue to be cut having previously been identified by means known to those skilled in the art. Typically, hibernating tissue can be 15 identified by injecting contrast medium into coronary vessels to identify regions of the heart into which the contrast medium does not flow due to obstruction of the vessels into which the medium is injected. In this case, the hibernating region will be identified by the lack of 20 flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels. Alternatively, the contrast medium can be injected directly into the heart chambers to identify areas within the chamber or chambers which have generally stagnant, pooled blood. If contrast 25 medium has been injected into the coronary vessels, those regions of the heart into which the contrast medium does

not flow, would be candidates for the RF TMR procedure.

If contrast medium is injected directly into the heart chambers, the regions of the heart adjacent to the generally stagnant pooled blood would be candidates for the RF TMR procedure.

Access to the patient's heart will generally be obtained percutaneously through aorta 12 and ventricle 14. Balloon 166 can be inflated to help shield pooled blood within the ventricle from RF energy. As shown in Figure 5, catheter 118 is advanced from a position A into the myocardium of the patient's heart at position B.

RF generator 26 is activated to emit RF energy from cutting tip 148. As cutting tip 148 is advanced into the myocardium, the RF energy loosens the material within lumen 162 from the heart. A plug of tissue 184 can then be aspirated through lumen 162 by vacuum generator 156.

The diameter of cutting tip 148 can be varied to vary the diameter of the channel formed by this procedure. Additionally, the RF output of RF generator can be varied by increasing pulse duration of the application of RF or the power of the RF radiation to speed tissue removal.

Numerous characteristics and advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only

illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The inventions's scope is, of course, defined in the language in which the appended claims are expressed.

What is claimed is:

A radio frequency activated catheter,
 comprising:

an elongate shaft having a proximal end and a distal end and a lumen therethrough extending between the proximal and distal ends;

a cutting tip disposed at the distal end of the shaft, the cutting tip having a proximal end a distal end and a lumen extending therebetween in fluid communication with the shaft lumen; and

means for connecting the cutting tip to a radio frequency generator.

- 2. A radio frequency activated catheter in accordance with claim 1, wherein the cutting tip is metallic.
- 3. A radio frequency activated catheter in accordance with claim 2, wherein the distal end of the cutting tip is sharpened.
- 4. A radio frequency activated catheter in accordance with claim 1, wherein the means for connecting includes wire.

5. A radio frequency activated catheter assembly, comprising:

- a first catheter including an elongate shaft having a proximal end and distal end, a lumen extending therethrough between the proximal and distal ends, and a cutting tip disposed at the distal end of the shaft, the cutting tip having a proximal end and a distal end, and a lumen extending therebetween in fluid communication with the shaft lumen;
 - a radio frequency generator;
- a means for connecting the cutting tip to the radio frequency generator; and
- a vacuum source connected to the catheter proximate the proximal end of the catheter and in fluid communication with the lumens.
- 6. A radio frequency activated catheter assembly in accordance with claim 5, further comprising a second catheter having a proximal end and a distal end and a lumen extending therebetween, and the radio frequency catheter being disposed at least partially within the lumen of the second catheter.
- 7. A radio frequency activated catheter assembly in accordance with claim 6, wherein the second catheter further comprises a balloon disposed at the distal end

thereof and an inflation lumen extending between the proximal and distal ends of the second catheter being in fluid communication with the balloon.

- 8. A radio frequency activated catheter assembly in accordance with claim 5, wherein the cutting tip is metallic.
- 9. A radio frequency activated catheter assembly in accordance with claim 8, wherein the distal end of the cutting tip is sharpened.
- 10. A radio frequency activated catheter assembly in accordance with claim 5, wherein the means for connecting includes wire.
- 11. A method of performing a transmyocardial revascularization, comprising the steps of:

providing a catheter including an elongate shaft having a proximal end and a distal end and a lumen extending therebetween, and a cutting tip disposed at the distal end of the shaft, the cutting tip having a proximal end and a distal end and lumen extending therebetween in fluid communication with the shaft lumen, the cutting tip being coupled to a radio frequency generator;

advancing the cutting tip to a patient's heart;
activating the radio frequency generator to deliver
radio frequency energy to the cutting tip; and
advancing the cutting tip into the myocardium of the
patient's heart to bore a channel therein.

- 12. A method of performing transmyocardial revascularization in accordance with claim 11, wherein the cutting tip is advanced into the patient's ventricle.
- 13. A method of performing transmyocardial revascularization in accordance with claim 12, further comprising the steps of:

providing a second catheter having a proximal end and a distal end and lumen extending therebetween;


disposing the second catheter over the first catheter such that the distal end of the first catheter is proximate the distal end of the second catheter;


bringing the distal end of the second catheter into contact with the patient's heart while the radio frequency catheter extends through the lumen of the second catheter;

inflating a balloon disposed at the distal end of the second catheter to isolate the cutting tip from the blood pool within the patient's ventricle.


14. A method of performing transmyocardial revascularization in accordance with claim 11, further comprising the step of aspirating tissue from within the cutting tip through the lumen of the first catheter.

Fig.1





SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/22591

A. CLASSIFICATION OF SUBJECT MATTER PIC(6) A-SIB 1739 US CL60641.45 According to International Patent Classification (PC) or to both national classification and IPC II. PIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: -600/373, 374; 606/28, 34, 37, 41, 45, 46; 607/119,122 Documentuition searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS Search Terms: transmyocardial revascularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US 5,403,311 A (ABELLE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X. US 5,370,675 A (EDWARDS et al.) 06 December 1994, Figs. 1-4, 5-10 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X. DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y. John Commission of the continuation of Box C. See patent family sanex. Special attention of cited documents: **A continuation of pacification and the continuation of Box C. See patent family sanex. **Special attention of cited documents: **A continuation of pacification of pacification of a box of the continuation of Box C. See patent family sanex. **Special attention of cited documents: **A continuation of pacification of c									
APS Careful to International Patent Classification (IPC) or to both national classification and IPC R. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 600973, 374; 60678, 34, 37, 41, 45, 46; 607/119,122 Discumentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS Search Terms: transmyocardial revescularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages X. US 5,403,311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X. US 5,370,675 A (EDWARDS et al.) 06 December 1994, Figs. 1-4, 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X. DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y. October 1996, entire document. L. Special caraginise of cited documents: *** *** *** *** *** *** ***									
According to International Patent Classification (PC) or to both national classification and IPC IR FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 600073, 374; 606/28, 34, 37, 41, 45, 46; 607/19,122 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS Search Terms: transmyocardial revascularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. U.S. 5, 403, 311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X. U.S. 5, 370, 675 A (EDWARDS et al.) 04 December 1994, Figs. 1-4, 5-10 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and test of disclosure. X. DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y. DE 296 09 350 A (EGGERS et al.) 04 November 1997, entire 1-14 U.S. 5, 683, 366 A (EGGERS et al.) 04 November 1997, entire 1-14 U.S. 5, 683, 366 A (EGGERS et al.) 04 November 1997, entire 1-14 Detection of the catual which may drow doubt on priently detailed or which is confident on which is confident or which is confident on which is confident on which is confident on which is confident or which is declarated and an all and other relations or which is confident on which is confident on which is confident on which is confident or which is declarated and the search of the confidence of the confidenc	(-)								
Minimum documentation searched (classification system followed by classification symbols) U.S.: 600/373, 374; 606/28, 34, 37, 41, 45, 46; 607/119,122 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS Concumentation searched other than minimum documentation C. DOCUMENTS CONSIDERED TO BE RELEVANT Cottegory* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. U.S. 5,403,311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X. U.S. 5,370,675 A (EDWARDS et al) 06 December 1994, Figs. 1-4, 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X. DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. I. 1, 12 I. 14 P.A. U.S. 5,683,366 A (EGGERS et al) 04 November 1997, entire document. I. 1, 12 I. 2 I. 3 I. 4 I. 4 I. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	According to International Patent Classification (IPC) or to both national classification and IPC								
U.S.: 600/373, 374; 606/28, 34, 37, 41, 45, 46; 607/19,122 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched start and		B. FIELDS SEARCHED							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) AIS Search Terms: transmyocardial revascularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. V. US 5,403,311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X. US 5,370,675 A (EDWARDS et al) 06 December 1994, Figs. 1-4, 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X. DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y. DE 296 09 350 A (EGGERS et al) 04 November 1997, entire document and fining the general state of the structure of the	Minimum do	cumentation searched (classification system followed	by classification symbols)						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS Search Terms: transmyocardial revascularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X	U.S. : 6	00/373, 374; 606/28, 34, 37, 41, 45, 46; 607/119,122							
APS Scarch Terms: transmyocardial revascularization C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X	Documentati	on searched other than minimum documentation to the	extent that such documents are included	in the fields searched					
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 5,403,311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X US 5,370,675 A (EDWARDS et al) 06 December 1994, Figs. 1-4, 11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y P,A US 5,683,366 A (EGGERS et al) 04 November 1997, entire document.		ata base consulted during the international search (nat	me of data base and, where practicable,	search terms used)					
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X		rms: transmyocardial revascularization							
US 5,403,311 A (ABELE et al.) 04 April 1995, Figs. 2, 3a, 5 and 6, and col. 3 lines 29-40. X	C. DOC	UMENTS CONSIDERED TO BE RELEVANT							
6, and col. 3 lines 29-40. X	Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.					
11-13, and 27-29; col. 3, lines 64-68; col. 12 lines 60-63; and rest of disclosure. X DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. 11, 12 14 P,A US 5,683,366 A (EGGERS et al) 04 November 1997, entire document. **T** **Torther documents are listed in the continuation of Box C. **Special categories of cited documents: **A** **Document defining the general state of the art which is not considered to be of particular relevance artifer document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered for involve an inventive step when the document is always the considered on an other standing date of another citation or other special reason (as specified) **O** **O** **O** **O** **Document published prior to the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is always to person skilled in the art **A** **O** **Date of mailing of the international search report **Date of Patients and Trademarks **DavID RUDDY	х		1-4						
Y DE 296 09 350 A (OSYPKA) 10 October 1996, entire document. Y P,A US 5,683,366 A (EGGERS et al) 04 November 1997, entire 1-14	x		5-10						
P,A US 5,683,366 A (EGGERS et al) 04 November 1997, entire 1-14 Further documents are listed in the continuation of Box C. Special categories of cited documenus: **Oscial categories of cited documenus: **A*** document defining the general state of the art which is not considered to be of particular relevance to be of particular relevance **E** earlier document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document at states alone **O*** document published prior to the international filing date but later than document published prior to the international filing date but later than document published prior to the international search **Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Y		14						
P,A US 5,683,366 A (EGGERS et al) 04 November 1997, entire 1-14 Further documents are listed in the continuation of Box C. Special categories of cited documents: A. Special categories of cited to entire the internation cannot be considered to involve an inventive step when the document is combined with one or more other such documents at combined with one or more other such documents are considered to involve an inventive step when the document is combined with one or more other such documents are considered to involve an inventive step when the document is combined with one or more other such document when the principle of particular relevance; the claimed i	x	DE 296 09 350 A (OSYPKA) 10 Octo	11, 12						
Further documents are listed in the continuation of Box C. See patent family annex. The special categories of cited documents: And document defining the general state of the art which is not considered to be of particular relevance. The document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alons The document referring to an oral disclosure, use, exhibition or other means The document referring to an oral disclosure, use, exhibition or other means The document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Washington, D.C. 20231	Y			14					
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document published on or after the international filing data cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Isler document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art '&' document member of the same patent family Date of mailing of the international search Tagemarks Date of fatents and Trademarks DAVID RUDDY DAVID RUDDY	P,A		1-14						
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document published on or after the international filing data cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Isler document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art '&' document member of the same patent family Date of mailing of the international search Tagemarks Date of fatents and Trademarks DAVID RUDDY DAVID RUDDY									
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing data document which may throw doubts on priority claim(s) or which is cited to establish the publication data of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or meant is taken alone *X* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family Date of mailing of the international search report 0 9 MAR 1998 Authorized officer DAVID RUDDY	Funt	ner documents are listed in the continuation of Box C	See patent family annex.						
to be of particular relevance: The earlier document published on or after the international filing data The document which may throw doubts on priority claim(s) or which is cited to establish the publication data of another citation or other special reason (as specified) The document referring to an oral disclosure, use, exhibition or other means The document published prior to the international filing data but later than the priority date claimed Date of the actual completion of the international search The document published prior to the international search The document published prior to the international search The document published prior to the international search The priority date claimed Date of the actual completion of the international search The priority date claimed The priority date claimed invention cannot be considered to involve an inventive step when the document is taken alone The document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone The document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined to involve an inventive step when the document is combined to involve an inventive step when the document is combined to involve an inventive step	date and not in conflict with the application but cited to understand								
C. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) **O.** document referring to an oral disclosure, use, exhibition or other means **P.** document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such comments, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search of mailing of the international search of ficer Aiane Amulta Formula David Ruddy David Ruddy David Ruddy	to	be of particular relevance	*X* document of particular relevance; the	ne claimed invention cannot be					
*A document referring to an oral disclosure, usa, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Commissioner, D.C. 20231	"L" do	neument which may throw doubts on priority claim(s) or which is	when the document is taken alone 'Y' document of particular relevance; the	ns claimed invention cannot be					
Date of the actual completion of the international search 16 FEBRUARY 1998 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Date of mailing of the international search report 0 9 MAR 1998 Authorized officer DAVID RUDDY	.O. do	cument referring to an oral disclosure, use, exhibition or other	combined with one or more other suc	h documents, such combination					
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 O 9 MAR 1998 Authorized officer Diane Smith from DAVID RUDDY	the								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Authorized officer Diane Smith from DAVID RUDDY	1	Date of the actual completion of the international search Date of mailing of the international search report							
Box PCT DAVID RUDDY Washington, D.C. 20231	16 FEBR	UARY 1998							
Washington, D.C. 20231	Commissio	mailing address of the ISA/US oner of Patents and Trademarks	1	smith f					
	Washingto	_	i						

THIS PAGE BLANK (USPTO)